Research Article
Topical Application of TAT-Superoxide Dismutase in Acupoints LI 20 on Allergic Rhinitis
Table 1
Characteristics of subjects in TTA, placebo, and TTN groups, mean (SEM).
| Parameter/treatment | TTA | Placebo | TTN | value | value |
| Baseline assessment | Number | 21 | 17 | 18 | NA | NA | Age (y), mean (SEM) | 30.0 (10.3) | 30.6 (12.4) | 30.2 (11.2) | 0.43 | 0.95 | Sex (M/F) | 8/13 | 7/10 | 7/11 | NA | NA | Skin test (number of positive patients) | Dust mite | 18 | 15 | 15 | NA | NA | Cat | 0 | 0 | 0 | NA | NA | Dog | 0 | 0 | 0 | NA | NA | Mold | 3 | 2 | 3 | NA | NA | Dust mite wheal (mm), mean (SEM) | 9.0 (1.2) | 9.4 (0.6) | 9.2 (0.7) | 0.18 | 0.54 | Course of disease (y), mean (SEM) | 6.5 (4.8) | 7.4 (5.1) | 7.5 (3.2) | 0.58 | 0.46 | Symptom score, mean (SEM) | Stuffiness | 1.8 (0.6) | 1.9 (0.6) | 1.8 (0.6) | 0.71 | 0.99 | Sneezing | 1.4 (0.6) | 1.4 (0.6) | 1.5 (0.8) | 0.89 | 0.66 | Rhinorrhea | 1.8 (0.8) | 1.9 (0.8) | 1.9 (0.6) | 0.78 | 0.67 | Itching | 1.9 (0.8) | 1.9 (0.9) | 1.9 (0.8) | 0.93 | 0.99 | Total | 6.9 (1.8) | 7.1 (1.8) | 7.1 (1.7) | 0.87 | 0.72 | Day 8 | Symptom score, mean (SEM) | Stuffiness | 1.3 (0.6) | 1.5 (0.5) | 1.6 (0.6) | 0.44 | 0.13 | Sneezing | 1.2 (0.6) | 1.2 (0.5) | 1.4 (0.6) | 0.93 | 0.31 | Rhinorrhea | 1.3 (0.6) | 1.8 (1.0) | 1.9 (0.6) | 0.09 | <0.01 | Itching | 1.3 (0.6) | 1.9 (0.6) | 1.9 (0.6) | <0.001 | <0.001 | Total | 5.1 (1.3) | 6.4 (1.2) | 6.8 (1.1) | <0.01 | <0.001 | Day 15 | Symptom score, mean (SEM) | Stuffiness | 0.8 (0.6) | 1.7 (0.6) | 1.6 (0.7) | <0.001 | <0.001 | Sneezing | 0.4 (0.6) | 1.4 (0.8) | 1.4 (0.6) | <0.001 | <0.001 | Rhinorrhea | 1.0 (0.7) | 1.5 (0.6) | 1.9 (0.6) | 0.01 | <0.001 | Itching | 0.8 (0.6) | 2.1 (0.7) | 2.0 (0.5) | <0.001 | <0.001 | Total | 3.0 (1.7) | 6.7 (1.2) | 6.9 (1.1) | <0.001 | <0.001 | Therapeutic response, number (percentage) | Deterioration | 1 (4.8%) | 2 (11.7%) | 3 (16.7%) | NA | NA | None | 3 (14.3%) | 14 (82.4%) | 15 (83.3%) | NA | NA | Moderate | 10 (47.6%) | 1 (5.9%) | 0 (0%) | NA | NA | Marked | 7 (33.3%) | 0 (0%) | 0 (0%) | NA | NA |
|
|
NA, not applicable. Two-sample -test comparing treatment means of TTA versus placebo. Two-sample -test comparing treatment means of TTA versus TTN.
|